3 enrolling by invitation. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension of SKY-0515 in Participants With Huntington's Disease SKY-0515 - Huntington's Disease (HD) | Phase 2 / Phase 3 | Enrolling by invitation | Skyhawk Therapeutics, Inc. | 500 | 2026-04-10 | 2026-07-24 |
| Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) Low-Intensity Walking Intervention, Control Group Intervention - Chemotherapy-related Cognitive Impairment | Phase 3 | Enrolling by invitation | Ellis Medicine | 100 | 2025-06-09 | 2025-08-12 |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Valbenazine - Chorea, Huntington | Phase 3 | Enrolling by invitation | Neurocrine Biosciences | 7 | 2024-04-24 | 2026-06-18 |
Huntington Disease (2) · Chemotherapy-Related Cognitive Impairment (1) · Cognitive Dysfunction (1) · Neurotoxicity Syndromes (1)
Cognition Disorders (3) · Mental Disorders (3) · Nervous System Diseases (3) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Chorea (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dementia (2) · Dyskinesias (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Movement Disorders (2) · Neurodegenerative Diseases (2)
valbenazine (1)
Ellis Medicine (1) · Neurocrine Biosciences (1) · Skyhawk Therapeutics, Inc. (1)
Australia (1) · Canada (1) · New Zealand (1) · United States (1)